#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic granulomatous disease Myotonic dystrophy Canavan disease Neuroendocrine cell hyperplasia of infancy Mastocytosis Neuronal ceroid lipofuscinosis Ductal adenocarcinoma of pancreas Mantle cell lymphoma Malignant melanoma Enteritis Fibrosarcoma Neuroendocrine tumour Osteogenesis imperfecta Progressive supranuclear palsy Pleomorphic leiomyosarcoma More trials…

    Learn about Rare Diseases

    Skin angiosarcoma Glycogen storage disease type II – Treatment Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information Von Willebrand’s disease – Trials in Disease Chordoma – Treatment Angiosarcoma non-metastatic – Treatment Fabry’s disease – Diagnostics Focal segmental glomerulosclerosis – Treatment Splenic marginal zone lymphoma – Treatment Proteus syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sotalol Cetrorelix Demeclocycline Hydrochloride Ecoo15 Atuliflapon Sot102 Mometasone Furoate Monohydrate Valganciclovir Hydrochloride Ioflupane (123I) Potassium Canrenoate Rbd4059 Asparaginase Pamidronate Disodium F125/10 Mosliciguat INCB123667 Bepranemab CARBACHOL Glipizide Nipocalimab More therapies…

    Learn about Your Condition

    Cervix carcinoma stage II Hypotransferrinaemia Systemic lupus erythematosus Triple negative breast cancer Myxoid liposarcoma Systemic sclerosis pulmonary Colorectal adenoma Corneal dystrophy Pituitary tumour benign Neoplasm Deafness Fatty acid oxidation disorder Interstitial lung disease Coronary artery occlusion Encephalitis Japanese B More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Safety and effectiveness study of PN6047 HCl in adults with peripheral neuropathic pain and mechanical allodynia

    Not yet recruiting

    2 1
    Spain

  • Study of serotonin system changes in early Parkinson’s disease using [11C]DASB and [11C]SB207145 PET imaging in people with SNCA gene mutations

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • (1-(11C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE
    • 3-AMINO-4-[2-[[METHYL((111C)METHYL)AMINO]METHYL]PHENYL]SULFANYLBENZONITRILE
    France

  • Study on the Safety and Effects of LY3884961 for Patients with Parkinson’s Disease and a GBA1 Mutation

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene
    The Netherlands

  • Study on Efgartigimod for Patients with Autoimmune Dementia

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Dementia
    Investigated Drugs:
    • Efgartigimod Alfa
    Germany

  • Study on the Effectiveness and Safety of Masitinib and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Masitinib
    • Riluzole
    France Germany Greece Latvia Slovenia Spain +1

  • Study on Zolpidem’s Effects in Patients with Vision Impairments, Disorders of Consciousness, and Neurotypical Volunteers

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • ZOLPIDEM TARTRATE
    • Mannitol
    Belgium
Previous Page
1 … 70 71 72 73 74 … 141
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!